Duke to Expand Aspirin PGx Study to Singapore | GenomeWeb

Duke University said this week that it is expanding an ongoing aspirin pharmacogenomics study to Singapore in an effort to broaden the study population for the project.

The study, which aims to identify individuals who are most likely to suffer dangerous blood clots despite regular aspirin therapy, is a joint venture of the Duke Institute for Genome Sciences & Policy and the Duke-National University of Singapore Graduate Medical School.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.